All molecules

We are constantly expanding our molecule library.

Please subcribe to our newsletter to be notified as soon as we add new molecules to opnMe.

MOLECULE FAQ | CONTACT US

FILTER

SGLT6

Apply now:

Call for collaboration proposals for an unprecedented, potent and selective SGLT6 inhibitor on novel disease indications.

Deadline February 28, 2018

Aurora B
BI 831266

BI 831266 is a potent and selective Aurora B inhibitor that inhibits cell proliferation and could be used as tool compound testing biological hypotheses.

ATX
BI-2545

BI-2545 inhibits human ATX with an IC50 of 2.2 nM. In human whole blood BI-2545 inhibits Autotaxin with an IC50 of 29 nM and in rat whole blood with an IC50 of 96 nM.

BCL6
BI-3802

BI-3802 is a single digit nanomolar BCL6::Co-repressor inhibitor which induces efficacious BCL6 protein degradation in several Diffuse large B-cell lymphoma (DLBCL) cell lines (e.g., DC50 = 20 nM in SU-DHL-4 cells).

BCL6
BI-3812

BI-3812 is a single digit nanomolar BCL6::Co-repressor inhibitor which also inhibits the BCL6::Co-repressor complex formation in cells (IC50 = 40 nM). BI-3812 is a classical PPI inhibitor probe compound for testing hypotheses around BCL6 biology in vitro.

CCR1
BI-9667

BI-9667 is a potent, selective human CCR1 antagonist with optimized drug-like properties.

CCR10
BI-6901

Our compound is the first small molecule inhibitor of the Chemokine receptor CCR10.1-3 It is a potent and selective compound and suitable for in vivo validation.

CDK8
BI-1347

BI-1347 is a selective nanomolar CDK8 inhibitor, suitable for testing biological hypotheses in vitro and also in vivo.

FAS
BI 99179

Our FAS in vivo tool compound BI 99179 is characterised by high potency, good selectivity and significant peripheral and central exposure upon oral administration in rats.

FLAP
BI 665915

BI 665915 demonstrates nanomolar FLAP binding potency and is a molecule suitable for testing biological hypotheses in vitro and also in vivo.

GR
BI 653048

BI 653048 is a “dissociated” GR agonist (displaying different transcriptional regulatory profiles between gene transrepression and transactivation) with selectivity for other nuclear receptors (MR, PR) and good drug-like properties.

HCV NS5B
BI 207127

BI 207127 (deleobuvir) is a highly potent inhibitor of the enzymatic function of NS5B, the RNA polymerase of HCV, and of viral replication  (~20 nM).

HCV NS3
BI-1230

BI-1230 is a single digit nanomolar inhibitor of HCV NS3 protease activity and of viral replication. BI-1230 was shown to be highly selective against other serine/cysteine proteases and to be suitable for in vivo studies.

HCV NS3
BI-1388

BI-1388 is a nanomolar to picomolar inhibitor of HCV NS3 protease activity and of viral replication for various HCV genotypes and for resistant mutants D168V and R155K.

LFA-1
BI-1950

BI-1950 potently inhibits the binding of LFA-1 to ICAM-1 with a KD value of 9 nM and the production of IL-2 in human PBMC and whole blood with an IC50 value of 3 nM and 120 nM, respectively.

NHE1
BI-9627

BI-9627 is a highly potent NHE1 inhibitor with low DDI potential, excellent pharmacokinetics, and good selectivity against NHE2 and NHE3.

PLK1
BI-2536

BI-2536 was the first potent and selective PLK1 inhibitor which entered clinical trials. It is a suitable in vitro and in vivo tool to study PLK function.

sEH
BI-1935

BI-1935 is a potent and selective small molecule inhibitor of Soluble epoxide hydrolase (sEH). In a biochemical binding assay h-sEH it shows an IC50 of 7 nM and is also highly active in a cellular Hep G2-DHET assay format (IC50 < 1 nM).

SYK
BI 1002494

BI 1002494 is due to its high potency, good physicochemical properties, suitable selectivity profile and low toxicity an excellent tool to explore SYK functions in vitro and in vivo.